FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013986093> ?p ?o ?g. }

• W2013986093 endingPage "21215" @default.
• W2013986093 startingPage "21215" @default.
• W2013986093 abstract "To evaluate procathepsin B, as well as endogenous inhibitors of cysteine proteases (cystatin B and cystatin C) in biological fluids as possible biomarkers of ovarian cancer. To observe levels of serum procathepsin B in different age groups.The sample (N=27) of women with gynaecological tumours included 18 patients with ovarian cancer (n=18) and 9 patients with benign ovarian tumours (n=9); 72 healthy women were in the control group. All patients were treated in Novosibirsk Regional Oncological Center, Russia. Serum samples of healthy women (n=40) aged 18-70 years were used as controls for common biomarker of ovarian cancer CA-125. In the Procathepsin B study, serum samples of healthy women (n=32) aged 18-40 years (n=14), 41-55 years (n=10) and 56-80 (n=8) years were used as controls.Common biomarker of ovarian cancer, CA-125, was assayed by using a commercial kit (Vector, Koltsovo, Novosibirsk Region, Russia). Procathepsin B was measured by means of a commercial kit for human procathepsin B (R&D, USA); cystatin C was measured by commercial ELISA kits for human (BioVendor, Czechia); cystatin B was measured by ELISA kits for human (USCN Life Science Inc., Wuhan, China). Statistical analysis was performed by one-way ANOVA (Statistica 10 Program).In the control group, serum procathepsin B concentration did not reveal age dependency. In the ovarian cancer group, both levels of serum procathepsin B and standard biomarker CA-125 increased significantly (both p<0.001) compared with the control group. In the benign ovarian tumour group, serum procathepsin B (p<0.001) and CA-125 (p=0.004) increased about 2.5- and 8-fold compared to the control group. Serum cystatin B level increased up to 1.7-fold in the ovarian cancer group compared to the control group. The increase of serum CA-125 was about 3.5-fold higher (p=0.017) and procathepsin B was 1.8-fold higher (p<0.05) in the ovarian cancer group compared to the benign tumour group. Cystatin B in ascites fluid increased equally in both ovarian cancer (p<0.001) and benign ovarian tumours group (p<0.05). Cystatin C concentration in ascites fluid increased only in patients with ovarian cancer (p<0.05) and did not change in the benign tumours group. Large increases of procathepsin B level (about 13-fold, p<0.001) and to a lesser degree of cystatin C (1.8-fold, p<0.05) and cystatin B levels (1.4 fold, p<0.001) were revealed in ascites fluids of patients with ovarian cancer compared to the control serum. The significant difference in serum procathepsin B levels was noted between the ovarian cancer and benign tumour groups (p<0.05), which could be used in differential diagnostics between malignant and benign gynaecological tumours.Serum procathepsin B demonstrated significant promise as a new biomarker of ovarian cancer." @default.
• W2013986093 created "2016-06-24" @default.
• W2013986093 creator A5015679089 @default.
• W2013986093 creator A5015942699 @default.
• W2013986093 creator A5022838394 @default.
• W2013986093 creator A5068138669 @default.
• W2013986093 creator A5071088268 @default.
• W2013986093 creator A5074823990 @default.
• W2013986093 date "2013-01-31" @default.
• W2013986093 modified "2023-10-10" @default.
• W2013986093 title "Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer" @default.
• W2013986093 cites W1494677644 @default.
• W2013986093 cites W1596775181 @default.
• W2013986093 cites W1607080847 @default.
• W2013986093 cites W167193550 @default.
• W2013986093 cites W1965920305 @default.
• W2013986093 cites W1968319976 @default.
• W2013986093 cites W2008641624 @default.
• W2013986093 cites W2014941869 @default.
• W2013986093 cites W2019384302 @default.
• W2013986093 cites W2030340060 @default.
• W2013986093 cites W2038427168 @default.
• W2013986093 cites W2076540449 @default.
• W2013986093 cites W2108490599 @default.
• W2013986093 cites W2137031950 @default.
• W2013986093 cites W2155999597 @default.
• W2013986093 cites W2165250619 @default.
• W2013986093 cites W2169558800 @default.
• W2013986093 cites W2169691126 @default.
• W2013986093 cites W2333425663 @default.
• W2013986093 cites W4234049326 @default.
• W2013986093 doi "https://doi.org/10.3402/ijch.v72i0.21215" @default.
• W2013986093 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3754495" @default.
• W2013986093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23986888" @default.
• W2013986093 hasPublicationYear "2013" @default.
• W2013986093 type Work @default.
• W2013986093 sameAs 2013986093 @default.
• W2013986093 citedByCount "21" @default.
• W2013986093 countsByYear W20139860932014 @default.
• W2013986093 countsByYear W20139860932015 @default.
• W2013986093 countsByYear W20139860932016 @default.
• W2013986093 countsByYear W20139860932017 @default.
• W2013986093 countsByYear W20139860932018 @default.
• W2013986093 countsByYear W20139860932019 @default.
• W2013986093 countsByYear W20139860932021 @default.
• W2013986093 countsByYear W20139860932022 @default.
• W2013986093 countsByYear W20139860932023 @default.
• W2013986093 crossrefType "journal-article" @default.
• W2013986093 hasAuthorship W2013986093A5015679089 @default.
• W2013986093 hasAuthorship W2013986093A5015942699 @default.
• W2013986093 hasAuthorship W2013986093A5022838394 @default.
• W2013986093 hasAuthorship W2013986093A5068138669 @default.
• W2013986093 hasAuthorship W2013986093A5071088268 @default.
• W2013986093 hasAuthorship W2013986093A5074823990 @default.
• W2013986093 hasBestOaLocation W20139860931 @default.
• W2013986093 hasConcept C121608353 @default.
• W2013986093 hasConcept C126322002 @default.
• W2013986093 hasConcept C143998085 @default.
• W2013986093 hasConcept C2779548226 @default.
• W2013986093 hasConcept C2780306776 @default.
• W2013986093 hasConcept C2780412452 @default.
• W2013986093 hasConcept C2780427987 @default.
• W2013986093 hasConcept C2781197716 @default.
• W2013986093 hasConcept C55493867 @default.
• W2013986093 hasConcept C71924100 @default.
• W2013986093 hasConcept C86803240 @default.
• W2013986093 hasConcept C90924648 @default.
• W2013986093 hasConceptScore W2013986093C121608353 @default.
• W2013986093 hasConceptScore W2013986093C126322002 @default.
• W2013986093 hasConceptScore W2013986093C143998085 @default.
• W2013986093 hasConceptScore W2013986093C2779548226 @default.
• W2013986093 hasConceptScore W2013986093C2780306776 @default.
• W2013986093 hasConceptScore W2013986093C2780412452 @default.
• W2013986093 hasConceptScore W2013986093C2780427987 @default.
• W2013986093 hasConceptScore W2013986093C2781197716 @default.
• W2013986093 hasConceptScore W2013986093C55493867 @default.
• W2013986093 hasConceptScore W2013986093C71924100 @default.
• W2013986093 hasConceptScore W2013986093C86803240 @default.
• W2013986093 hasConceptScore W2013986093C90924648 @default.
• W2013986093 hasIssue "1" @default.
• W2013986093 hasLocation W20139860931 @default.
• W2013986093 hasLocation W20139860932 @default.
• W2013986093 hasLocation W20139860933 @default.
• W2013986093 hasLocation W20139860934 @default.
• W2013986093 hasOpenAccess W2013986093 @default.
• W2013986093 hasPrimaryLocation W20139860931 @default.
• W2013986093 hasRelatedWork W2085777459 @default.
• W2013986093 hasRelatedWork W2292680196 @default.
• W2013986093 hasRelatedWork W2326788508 @default.
• W2013986093 hasRelatedWork W2335730662 @default.
• W2013986093 hasRelatedWork W2590408703 @default.
• W2013986093 hasRelatedWork W2897112912 @default.
• W2013986093 hasRelatedWork W2902032586 @default.
• W2013986093 hasRelatedWork W3031103682 @default.
• W2013986093 hasRelatedWork W4226205612 @default.
• W2013986093 hasRelatedWork W90446921 @default.
• W2013986093 hasVolume "72" @default.
• W2013986093 isParatext "false" @default.

• next